- Trial phase
- Phase 1
- Time to market
- At least 5-7 years if successful (currently in Phase 1 dose-escalation; typical ADC development timelines from Phase 1 to approval span 5-8 years)
- Why 5/10
- The next hard catalyst is the initial Phase 1 safety data readout from the dose-escalation trial (NCT07085091), expected in the second half of 2026. ALX2004 is the company's second pipeline asset behind lead CD47 blocker evorpacept, so this catalyst is meaningful for pipeline diversification but not a make-or-break binary for ALXO, which has cash runway through 1H 2028.
Investors should watch for the Phase 1 safety data readout in 2H 2026, which will be the first clinical data for this program. Positive results could unlock a $10M contingent tranche from HSVC's $50M credit facility. The data will also validate ALXO's internal ADC platform and inform whether the drug can differentiate in a competitive EGFR-targeted ADC landscape where MRG003 (becotatug vedotin) was already approved in China in November 2025.
Price Chart
Executive Summary
ALX2004 is ALX Oncology's second clinical-stage pipeline candidate, a novel EGFR-targeted antibody-drug conjugate (ADC) using a topoisomerase I inhibitor payload with a proprietary linker designed to minimize off-tumor skin toxicity. It entered Phase 1 clinical trials in August 2025 (NCT07085091) in EGFR-expressing solid tumors (NSCLC, HNSCC, ESCC, CRC). The dose-escalation has cleared two cohorts without DLTs, and initial safety data is expected in the second half of 2026. ALX2004 is the company's second program behind evorpacept (CD47 blocker), but represents important pipeline diversification and validation of ALXO's internal ADC platform. The EGFR-targeted ADC space is competitive, with MRG003 (becotatug vedotin) becoming the world's first approved EGFR ADC in China in November 2025.
How It Works
ALX2004 is an antibody-drug conjugate (ADC), a targeted cancer therapy that works like a guided missile. One part of the drug (the antibody) seeks out and binds to EGFR, a protein found on the surface of many cancer cells. The other part delivers a chemotherapy payload (a topoisomerase I inhibitor) directly inside the cancer cell to kill it. ALX2004 uses a proprietary linker designed to keep the payload stable in the bloodstream and release it only inside tumor cells, which could reduce side effects like skin toxicity seen with other EGFR-targeting drugs.
Trial Status
Phase 1 first-in-human dose-escalation trial (NCT07085091) is actively enrolling. First patient dosed August 2025. Dose cohorts at 1 mg/kg and 2 mg/kg cleared without dose-limiting toxicities; 4 mg/kg cohort currently enrolling. Initial safety data from the dose-escalation phase is anticipated in the second half of 2026 (was originally guided for H1 2026, then pushed to 2H 2026 as of the Q4 2025 earnings call in February 2026). The trial is enrolling patients with previously treated advanced/metastatic NSCLC, HNSCC, ESCC, and CRC.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 ALX2004 initial safety data readout from dose-escalation, expected in 2H 2026 (likely Q3-Q4 2026)
- Evorpacept (lead asset) pivotal ASPEN-09 Phase 2 data expected mid-2027, this is ALXO's primary near-term value catalyst
- Potential $10M contingent tranche from HSBC credit facility tied to positive ALX2004 Phase 1 safety data
- Jefferies Global Healthcare Conference participation (June/July 2026), pipeline updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALX ONCOLOGY HOLDINGS INC 8-K ALXO ·Originating report